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Albuminuria as a predictor of cardiovascular and renal out-
comes in people with known atherosclerotic cardiovascular
disease.
Background. Microalbuminuria predicts elevated cardiovas-
cular risk in those with and without diabetes. In diabetes, mi-
croalbuminuria also heralds overt diabetic nephropathy. The
predictive value of albuminuria below the microalbuminuria
cutoff, and the development of overt nephropathy in nondia-
betics with microalbuminuria, have not been well studied. We
review findings of the HOPE Study.
Methods. The HOPE Study database includes data on first
morning urine albumin/creatinine ratio (ACR) in 9043 partici-
pants at baseline, and in 7674 participants at baseline and at last
follow-up. Inclusion criteria were known vascular disease or dia-
betes, plus one other cardiovascular risk facto; exclusion criteria
included heart failure or known impaired left ventricular func-
tion, dipstick-positive proteinuria (>1+), and serum-creatinine
>2.3 mg/dL (200 lmol/L). Microalbuminuria was defined as an
ACR ≥ 2 mg/mmol.
Results. Microalbuminuria at baseline approximately dou-
bled the relative risk (RR) of the primary outcome (myocar-
dial infarction, stroke, or CV death). For every 1 mg/mmol rise
of ACR, even below the level of microalbuminuria, the ad-
justed hazard of the primary outcome increased by about 15%.
Baseline microalbuminuria predicted subsequent clinical pro-
teinuria, RR 17.5, similarly in participants without and with di-
abetes. New microalbuminuria developed in 1542 participants,
and clinical proteinuria in 317.
Conclusion. Albuminuria is a continuous risk factor for CV
events even below the level of microalbuminuria. Microalbu-
minuria predicts clinical proteinuria in nondiabetics.
Microalbuminuria was initially defined as a range of
dipstick-negative albuminuria that predicted future overt
nephropathy in people with type 1 diabetes mellitus [1–
3]. Further research established similar associations in
people with type 2 diabetes mellitus, albeit with wider
estimates of risk than those reported for type 1 diabetes
[1–3]. The significance of microalbuminuria as a risk fac-
Key words: diabetes, myocardial infarction, stroke, ramipril, ACE in-
hibitor, angiotensin, cardiovascular, proteinuria.
C© 2004 by the International Society of Nephrology
tor for renal outcomes in nondiabetic people is even less
clear [4].
In addition to predicting renal disease, microalbumin-
uria is a powerful predictor of cardiovascular events both
in people with and without diabetes mellitus [5–15]. The
fact that microalbuminuria predicts both cardiovascular
and renal events, and the fact that microalbuminuria is
observed in 10% to 15% of adults, and in about 30%
of people with diabetes mellitus [1], highlights the im-
portance of identifying affected people. For example,
the INSIGHT Study evaluated an extensive list of car-
diovascular risk factors in hypertensive subjects, and al-
buminuria turned out to be the single most important
[16].
The HOPE Study was a prospective trial of 4.5 years
duration that included people with and without a history
of diabetes who were at risk for cardiovascular events
[17–20]. People with a serum-creatinine ≤2.3 mg/dL
(200 lmol/L) who had no evidence of clinical protein-
uria were included. The urine albumin/creatinine ratio
(ACR) was measured at baseline and at last follow-up in
all participants; in people with diabetes it was also mea-
sured at one year. This paper reviews the HOPE Study
observations regarding albuminuria as a predictor of car-
diovascular and renal events [4, 21].
RESULTS OF THE HOPE STUDY
Cardiovascular impact of baseline microalbuminuria
Microalbuminuria (albumin/creatinine ratio, ACR,
≥2 mg/mmol or 18 mg/g) was detected in 1140 (32.6%)
diabetic participants, and 823 (14.8%) nondiabetic par-
ticipants at baseline. Figure 1 displays the risk for im-
portant outcomes according to the presence or absence
of microalbuminuria. After controlling for randomiza-
tion to ramipril, baseline microalbuminuria increased the
risk of major cardiovascular events by 1.83-fold (95% CI
1.64–2.05; P < 0.0001); all-cause mortality by 2.09-fold
(95% CI 1.84–2.38); and hospitalization for heart fail-
ure by 3.23-fold (95% CI 2.54–4.10). Similar estimates
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Fig. 1. Adjusted risk for cardiovascular outcomes according to the
presence of microalbuminuria at baseline in HOPE. The primary out-
come was the composite of myocardial infarction, stroke, and CV death.
Mortality, all-cause mortality; CHF, hospitalization for congestive heart
failure. Open bars, all participants (N = 9043); striped bars, participants
with a history of diabetes mellitus at baseline (N = 3498); black bars,
participants with no history of diabetes mellitus at baseline (N = 5545).
RR and 95% CI are given.
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Fig. 2. Adjusted relative risk for cardiovascular outcomes according
to quartile of albuminuria at baseline in HOPE. The data refer to all
participants (N = 9043). The RR of the lowest quartile is set at 1; open
bars, RR for the primary outcome (see legend of Fig. 1); striped bars, RR
for all cause mortality; black bars, RR for hospitalization for congestive
heart failure. RR and 95% CI are given.
were noted in individuals with and without a history of
diabetes. These strong associations persisted after con-
trolling for other cardiovascular risk factors in placebo
and ramipril-treated individuals.
Cardiovascular impact of albumin/creatinine ratio below
the microalbuminuria threshold
Figure 2 shows the relationship between the risk of
cardiovascular outcomes and baseline ACR; this rela-
tionship extended into the “premicroalbuminuric” range.
Indeed, this linear trend for major cardiovascular events,
all-cause mortality, and hospitalization for heart failure in
all participants was significant, after controlling for age,
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Fig. 3. Progression of proteinuria in HOPE. The percentage of partic-
ipants with measurements of albuminuria both at baseline and at study
end (N = 7674, history of diabetes in 3223) that developed new mi-
croalbuminuria (MA, left panel), new clinical or overt proteinuria (PR,
middle panel) is given. The right panel depicts the percentage of partic-
ipants with microalbuminuria at baseline (N = 1619, diabetes in 1013)
that developed clinical proteinuria. Open bars, all participants; striped
bars, participants with a history of diabetes mellitus at baseline; black
bars, participants with no history of diabetes mellitus at baseline. RR
and 95% CI are given.
gender, systolic blood pressure, diastolic blood pressure,
waist/hip ratio, diabetes status (presence or absence in
all participants and the glycated hemoglobin in diabetic
participants) (P < 0.0001), and after randomization to
ramipril (P for trend <0.0001).
Renal impact of baseline microalbuminuria
Microalbuminuria predicted clinical proteinuria re-
gardless of a history of diabetes. This risk was inde-
pendent of other cardiovascular risk factors, including
hypertension. Approximately 5% of microalbuminuric
participants with no history of diabetes, and 20% of mi-
croalbuminuric participants with a history of diabetes de-
veloped clinical proteinuria or overt nephropathy within
four years (Fig. 3). In participants with microalbumin-
uria, the risk for clinical proteinuria/overt nephropathy
was about 15- to 20-fold higher than in participants with-
out microalbuminuria.
Any progression of proteinuria occurred in 1859 par-
ticipants (24%); this includes progression from normal
urine albumin excretion to either microalbuminuria or
to clinical proteinuria, or the progression from microal-
buminuria to clinical proteinuria. Progression was more
often observed in diabetic (N = 3243) than in nondia-
betic (N = 4431) participants (34% vs. 17%, P < 0.001).
New microalbuminuria developed 1542/6055 participants
(25.5%, comprising 38.2% of the diabetic and 18.1% of
the nondiabetic participants) (Fig. 3). New clinical pro-
teinuria developed in 317/7674 participants (4.1%, com-
prising 8% of the diabetic and 1% of the nondiabetic
participants) (Fig. 3).
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DISCUSSION
The HOPE and MICRO-HOPE trials predominantly
included people with definitive evidence of atheroscle-
rotic cardiovascular disease [17] and a large number of
people with diabetes mellitus [20]. As such, its findings
are directly applicable to the patients that internists and
family physicians encounter on a daily basis.
How should we interpret albuminuria levels that are
below and above the threshold for microalbuminuria
(ACR 2 mg/mmol)?
The cardiovascular outcome data presented here show
that microalbuminuria predicts hospitalization for con-
gestive heart failure and all-cause mortality. This is
new information in addition to the growing number of
prospective studies that portrayed microalbuminuria as
a strong independent risk for CV events [5–15]. Most
importantly, we show that the relationship between albu-
minuria and all cardiovascular events is not restricted to
the microalbuminuria range. Indeed, they indicate that
the ACR is a continuous risk factor for CV disease, and
that the relationship extends well below currently ac-
cepted screening thresholds for microalbuminuria [21].
As such, the ACR is similar to the blood pressure, with
no clear “normal” cutoff. This is consistent with a re-
cent prospective study in which individuals with an albu-
min/creatinine ratio >0.65 mg/mmol had a relative risk
for ischemic heart disease of 2.3 (P = 0.002) compared to
people with a lower degree of albuminuria [22]. Thus, an
albumin/creatinine ratio of 2.0 mg/mmol (18 mg/g) may
not be relevant when considering the risk for cardiovas-
cular outcomes; lower degrees of albuminuria are also
predictive.
The renal outcome data show that the microalbumin-
uria cutoff is relevant as a strong risk factor for the de-
velopment of clinical proteinuria in both diabetic and
nondiabetic people at high risk for cardiovascular events.
We also confirm the predictive value of microalbumin-
uria for overt nephropathy [1] in type 2 diabetes, with
about 5% new cases per year. We do not have further
nephrologic details of the participants. Based on the high
likelihood of generalized atherosclerosis in most par-
ticipants of the HOPE trial, and on the exclusion of
proteinuric participants, we can assume that the progres-
sion from microalbuminuria to clinical proteinuria in the
nondiabetic people is suggestive evidence of progressive
nephrosclerosis [23]. We do not know, however, whether
this progression heralds future renal failure, as is the case
in diabetes. Considering the high number of patients with
terminal renal failure due to nephrosclerosis [23–26], the
latter point deserves further study.
Progression of albuminuria, defined as a new microal-
buminuria or new clinical proteinuria, was found in a
substantial number of participants in the HOPE Study,
although they were extensively treated by antihyperten-
sives, statins, aspirin, etc. Also, only participants with con-
trolled hypertension could be included, and most were
normotensive at baseline [18, 20]. Nevertheless, progres-
sion of albuminuria was found in one of five participants
in 4.5 years, in one of three participants with diabetes,
and in one of seven without diabetes. In particular, one
of three participants with diabetes developed new mi-
croalbuminuria, and one of five diabetic participants with
microalbuminuria developed overt nephropathy [4].
From trials in patients with renal diseases and signif-
icant proteinuria it is known that the amount of pro-
teinuria on treatment is also predictive of future renal
outcomes [27]. Unpublished data of the MICRO-HOPE
Study suggest that this is also true for cardiovascular
events. At least, microalbuminuria at baseline and dur-
ing treatment was equally predictive for cardiovascular
events.
The data reported here have a number of limitations.
A substantial number of participants could not provide
follow-up urines, mainly because they had died. It is con-
ceivable or even likely that participants that died during
the trial developed new microalbuminuria or new pro-
teinuria more frequently than did those that did not die
[4]. Therefore, the data may underestimate the true rate
of progression of proteinuria in a population at high car-
diovascular risk. Urine albumin was measured only once
at each time point. Albuminuria is variable and most or-
ganizations recommend that 2 out of 3 measurements
need to be positive to establish the presence of microal-
buminuria [1, 2]. Nevertheless, the large sample size and
the fact that the ACR was assayed centrally, can compen-
sate for the variance associated with only one measure-
ment. Moreover, the fact that the regression dilution bias
introduced by a single measurement of a risk factor is an
underestimate and not an overestimate of the importance
of that risk factor [28] provides further indication of the
robustness of these observations.
CONCLUSIOIN
Taken together, these observations support the con-
clusion that albuminuria reflects underlying vascular
disease. These data also suggest that measurement of
urinary albumin—before starting treatment and during
treatment—may be a useful tool to identify both diabetic
and nondiabetic patients at high risk of renal and cardio-
vascular disease. These patients can then be more aggres-
sively targeted for preventive interventions.
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